PD-L1 overexpression by tumors (eg, in breast, lung, melanoma, liver, head and neck, and colon tumors) might enable tumor cells to block antitumor immune responses, and is associated with poor prognosis [6,8,9]. The gene discussed is CD274; the disease is neoplasm.